Paweł Sowa

Dr. Paweł Sowa

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

7 August 2021 in Vaccines
Verified
Journal Article
Open access
PDF file
PSPaweł Sowa
Paweł Sowa
ŁKŁukasz Kiszkiel
Łukasz Kiszkiel
Piotr LaskowskiPiotr Laskowski
Piotr Laskowski
Maciej AlimowskiMaciej Alimowski
Maciej Alimowski
LSLukasz Szczerbinski
Lukasz Szczerbinski
Karol Adam KaminskiKarol Adam Kaminski
Karol Adam Kaminski
Since the declaration of the SARS-CoV-2 pandemic confirmed by World Health Organization, work on the development of vaccines has been stimulated. When vaccines are commonly available, a major problem is persistent vaccine hesitancy in many European countries. The main goal of our study was to understand the multidimensional factors inducing this phenomenon in Poland. Our study was carried out at the third wave’s peak of the pandemic, with record rates of daily cases and deaths associated with COVID-19. The results indicate that vaccine hesitancy/acceptability should always be considered in an interdisciplinary manner and according to identified factors where most negative attitudes could be altered. Our analyses included the assessment of a representative quota sample of adult Poles (N = 1000). The vaccine hesitancy in the studied group reached 49.2%. We performed stepwise logistic regression modeling to analyze variables set into six trajectories (groups) predicting the willingness to vaccinate. Apart from typical, socio-demographic and economic determinants, we identified the fear of vaccines’ side effects, beliefs in conspiracy theories and physical fitness. We were also able to establish the order of importance of factors used in a full model of all impact trajectories.

29 October 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
ESEmilia Sawicka
Emilia Sawicka
KBKinga Bondarczuk
Kinga Bondarczuk
WBWitold Bauer
Witold Bauer
MNMagdalena Niemira
Magdalena Niemira
ASAnna Szalkowska
Anna Szalkowska
Karol Adam KaminskiKarol Adam Kaminski
Karol Adam Kaminski
Despite knowledge of classical coronary artery disease (CAD) risk factors, the morbidity and mortality associated with this disease remain high. Therefore, new factors that may affect the development of CAD, such as the gut microbiome, are extensively investigated. This study aimed to evaluate gut microbiome composition in CAD patients in relation to the control group. We examined 169 CAD patients and 166 people in the control group, without CAD, matched in terms of age and sex to the study group. Both populations underwent a detailed health assessment. The microbiome analysis was based on the V3–V4 region of the 16S rRNA gene (NGS method). Among 4074 identified taxonomic units in the whole population, 1070 differed between study groups. The most common bacterial types were Firmicutes, Bacteroidetes, Proteobacteria, and Actinobacteria. Furthermore, a higher Firmicutes/Bacteroidetes ratio in the CAD group compared with the control was demonstrated. Firmicutes/Bacteroidetes ratio, independent of age, sex, CAD status, LDL cholesterol concentration, and statins treatment, was related to altered phosphatidylcholine concentrations obtained in targeted metabolomics. Altered alpha-biodiversity (Kruskal–Wallis test, p = 0.001) and beta-biodiversity (Bray–Curtis metric, p < 0.001) in the CAD group were observed. Moreover, a predicted functional analysis revealed some taxonomic units, metabolic pathways, and proteins that might be characteristic of the CAD patients’ microbiome, such as increased expressions of 6-phospho-β-glucosidase and protein-N(pi)-phosphohistidine-sugar phosphotransferase and decreased expressions of DNA topoisomerase, oxaloacetate decarboxylase, and 6-beta-glucosidase. In summary, CAD is associated with altered gut microbiome composition and function.

28 January 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MCMałgorzata Chlabicz
Małgorzata Chlabicz
JJJacek Jamiołkowski Jacek Jamiołkowski
Jacek Jamiołkowski Jacek Jamiołkowski
WŁWojciech Łaguna
Wojciech Łaguna
MDMarlena Dubatówka
Marlena Dubatówka
PSPaweł Sowa
Paweł Sowa
Karol Adam KaminskiKarol Adam Kaminski
Karol Adam Kaminski
Background: Cardiovascular diseases (CVD) are still the leading cause of death in developed countries. The aim of this study was to calculate the potential for CV risk reduction when using three different prevention strategies to evaluate the effect of primary prevention. Methods: A total of 931 individuals aged 20–79 years old from the Bialystok PLUS Study were analyzed. The study population was divided into CV risk classes. The Systematic Coronary Risk Estimation (SCORE), Framingham Risk Score (FRS), and LIFE-CVD were used to assess CV risk. The optimal prevention strategy assumed the attainment of therapeutic goals according to the European guidelines. The moderate strategy assumed therapeutic goals in participants with increased risk factors: a reduction in systolic blood pressure by 10 mmHg when it was above 140 mmHg, a reduction in total cholesterol by 25% when it was above 190 mg/dL, and a reduction in body mass index below 30. The minimal prevention strategy assumed that CV risk would be lowered by lifestyle modifications. The greatest CV risk reduction was achieved in the optimal model and then in the minimal model, and the lowest risk reduction was achieved in the moderate model, e.g., using the optimal model of prevention (Model 1). In the total population, we achieved a reduction of −1.74% in the 10-year risk of CVD death (SCORE) in relation to the baseline model, a −0.85% reduction when using the moderate prevention model (Model 2), and a −1.11% reduction when using the minimal prevention model (Model 3). However, in the low CV risk class, the best model was the minimal one (risk reduction of −0.72%), which showed even better results than the optimal one (reduction of −0.69%) using the FRS. Conclusion: A strategy based on lifestyle modifications in a population without established CVD could be more effective than the moderate strategy used in the present study. Moreover, applying a minimal strategy to the low CV risk class population may even be beneficial for an optimal model.

28 December 2022 in Journal of Affective Disorders
Verified
Journal Article
Closed access
MSMarco Solm
Marco Solm
TTTrevor Thompson
Trevor Thompson
AEAndrés Estradé
Andrés Estradé
Agorastos AgorastosAgorastos Agorastos
Agorastos Agorastos
Joaquim RaduàJoaquim Raduà
Joaquim Raduà
CCChristoph Correll
Christoph Correll

SSSebastian Adam Sołomacha
Sebastian Adam Sołomacha
PSPaweł Sowa
Paweł Sowa
ŁKŁukasz Kiszkiel
Łukasz Kiszkiel
Piotr LaskowskiPiotr Laskowski
Piotr Laskowski
Maciej AlimowskiMaciej Alimowski
Maciej Alimowski
Karol Adam KaminskiKarol Adam Kaminski
Karol Adam Kaminski
The outbreak of the COVID-19 pandemic caused the healthcare system to drastically reduce in-person visits and suddenly switch to telemedicine services to provide clinical care to patients. The implementation of teleconsultation in medical facilities was a novelty for most Polish patients. In Poland, the main telehealth services were provided in the form of telephone consultations. The aim of this study is to determine patients’ perceptions of telemedicine in the context of their experiences with the healthcare system during the COVID-19 pandemic. In this study, we presented how the evaluation of telemedicine services from the perspective of patients in Poland changed in the context of the ongoing pandemic. We conducted two surveys (year by year) on a representative quota sample of the Polish population (N = 623). This ensured that our observations took into account the evolution of views on telemedicine over time. We confirmed the well-known relationship that innovations introduced in the healthcare sector require a longer period of adaptation. We also identified significant concerns that limit the positive perception of telemedicine and compared them with experiences described in other countries.